AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Use of Quantitative Ultrasound to Guide Adaptive Chemotherapy Among Women With Breast Cancer

RecruitingNAAges 18 Years - anyFemaleSunnybrook Health Sciences Centre
💬

In plain words

What the trial is, and whether it could suit you

The primary objective of this study is to assess the feasibility of randomizing breast cancer patients to quantitative ultrasound to guide adaptive Neoadjuvant Chemotherapy as compared to standard clinical monitoring and therapy. The Investigators have previously demonstrated that high-frequency ultrasound and spectroscopy, and recently conventional-frequency ultrasound and spectroscopy may be used to detect cell death in vitro, in situ and in vivo. The method can detect different forms of cell death and has been demonstrated to be sensitive to apoptotic, necrotic and mitotic cell death. By detecting cell death early in a treatment on the order of hours to days, rather than traditional anatomical assessments that take place weeks to months after the completion of therapy, ineffective therapies could be switched to more efficacious treatments or aggressive salvage therapy which has shown

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: 1. Women ≥ 18 years of age 2. Diagnosis of breast cancer with a primary tumour \>2cm in size 3. With conditions meeting criteria for chemotherapy administration 4. Normal hematological blood counts (hemoglobin ≥ 100 g/l, platelet count ≥ 100 x 109, absolute neutrophil count ≥ 2.0 x109 cells per L) 5. Creatinine ≤175 µmol/L 6. Liver enzymes (AST and ALT) ≤ 1.5 times upper limit of normal 7. Cardiac function (left ventricular ejection fraction) ≥55% 8. Eligible for neoadjuvant chemotherapy. Exclusion Criteria: 1. Inflammatory breast cancer 2. Contraindications to neoadjuvant treatment including pregnancy or lactation 3. Past medical history of connective tissue disease 4. Past history of dermatologic disease involving the breast 5. Eastern Cooperative Group Status (ECOG) ≥3 6. No peripheral neuropathy of a severity of grade ≥2 7. Evidence of distant metastatic disease 8. Known sensitivity to components present in ultrasound gel.
💊

What it tests

  • Quantitative ultrasound to guide adaptive chemotherapy
📍

Where

1 site
Sunnybrook Health Sciences Centre
Toronto, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy